Welcome to our dedicated page for Koru Med Sys news (Ticker: KRMD), a resource for investors and traders seeking the latest updates and insights on Koru Med Sys stock.
KORU Medical Systems Inc (KRMD) specializes in innovative subcutaneous infusion systems for critical therapies. This hub provides authorized updates about the company's medical device developments, regulatory milestones, and strategic initiatives.
Investors and healthcare professionals will find timely announcements including product launch details, financial disclosures, and manufacturing updates. Our curated collection ensures access to verified information about FREEDOM infusion systems and related technologies.
Key updates cover FDA clearances, partnership announcements, clinical application insights, and operational developments. All content maintains strict compliance with financial disclosure regulations and medical device reporting standards.
Bookmark this page for streamlined access to KRMD's latest advancements in immunoglobulin therapy delivery systems. Check regularly for official updates directly impacting the medical device sector and chronic care treatment landscapes.
KORU Medical Systems (NASDAQ: KRMD), a medical technology company specializing in large volume subcutaneous infusion solutions, has announced it will release its first quarter 2025 financial results on Wednesday, May 7, 2025.
The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. U.S. and Canadian participants can join via (877)-407-0784, while international callers should use (201)-689-8560. The webcast will be available on KORU Medical's website and archived for six months.
KORU Medical Systems (NASDAQ: KRMD) reported strong financial results for Q4 and full year 2024, with significant growth across all business segments. Q4 net revenues reached $8.8 million, up 23% year-over-year, while full-year revenues hit $33.6 million, an 18% increase.
The company's Core business saw Q4 revenues of $8.2 million (+19% YoY), while Novel Therapies revenue grew 122% to $0.7 million. Gross margin improved to 62.9% in Q4 and 63.4% for the full year. The company ended 2024 with $9.6 million in cash, achieving positive cash flow of $0.8 million in Q4.
For 2025, KORU Medical projects net revenues between $38.0-$39.0 million (13-16% growth), with gross margins of 61-63%. The company expects to be operational cash flow positive for full year 2025. Additionally, the Novel Therapies business will be renamed to Pharma Services and Clinical Trials (PST) starting Q1 2025.
KORU Medical Systems (NASDAQ: KRMD) has announced it will release its fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025. The company will host a conference call and webcast at 4:30 p.m. ET on the same day, where management will discuss financial results and provide a corporate update.
The conference call will be accessible via phone for U.S. and Canadian participants at (877)-407-0784, and international callers at (201)-689-8560. A live and archived webcast will be available on the company's investor relations website for six months.
KORU Medical Systems (NASDAQ: KRMD) has announced a significant agreement with a global pharmaceutical company to develop and seek regulatory clearance for a next-generation subcutaneous immunoglobulin (SCIg) therapy infusion system. The project involves collaboration with SCHOTT Pharma and aims to create a platform infusion system compatible with both vial and prefilled syringe formats.
The innovative system will integrate KORU Medical's infusion technology with SCHOTT TOPPAC® prefillable polymer syringes (PFS). This development is expected to be the first of multiple joint projects with SCHOTT, focusing on providing a more convenient infusion experience for SCIg patients through an easy-to-use system that facilitates home therapy.
KORU Medical Systems (NASDAQ: KRMD) announced a collaboration with a global pharmaceutical manufacturer for a Phase III clinical trial exploring an expanded indication of a commercialized drug therapy. The trial targets a rare renal disorder affecting approximately 30,000 patients with a projected 300,000 annual infusions.
The Phase III trial will evaluate the safety, efficacy, and performance of the drug in treating patients with kidney transplant complications. The company's Freedom Infusion System currently administers over 2 million infusions annually. Upon successful trial completion, KORU Medical will gain access to a new patient base in the rare renal disorder segment.
KORU Medical Systems (KRMD) has announced preliminary unaudited results for Q4 and full year 2024, showing strong growth and improved financial performance. The company reported preliminary Q4 2024 net revenues of $8.9 million, representing a 23% growth compared to the previous year. Full-year 2024 net revenues reached $33.7 million, an 18% increase year-over-year.
The company ended the period with a cash balance of $9.6 million, achieving positive cash flow of $0.8 million in Q4. The full-year cash burn was $1.9 million, showing a 67% improvement from the previous year. KORU Medical has reported success in winning US market share, expanding internationally, and progressing with new drug therapy approvals while improving margins and maintaining disciplined cash management.
KORU Medical Systems (NASDAQ: KRMD), a medical technology company specializing in large volume subcutaneous infusion solutions, has announced its participation in Piper Sandler's 36th Annual Healthcare Conference. The Company's management will present on December 5, 2024, at 11:00 am ET. Investors and interested parties can access both the live and archived webcast through the News/Events page in the Investors section of KORU Medical's website.
KORU Medical Systems reported strong Q3 2024 financial results with net revenues of $8.2 million, representing a 17% increase year-over-year. The company achieved notable growth across segments, with core business up 11% and novel therapies growing 276%. Gross profit increased 19% to $5.2 million, with improved gross margin of 63%. Based on strong performance, KORU raised its full-year 2024 guidance, projecting net revenue of $32.75-$33.25 million (15-17% growth) and gross margin of 62-63%. The company ended Q3 with $8.8 million in cash and expects to achieve cash flow breakeven in Q4 2024.
KORU Medical Systems (NASDAQ: KRMD), a leading medical technology company, will participate in two upcoming investor conferences. The company focuses on developing, manufacturing, and commercializing innovative large volume subcutaneous infusion solutions. The management team will attend the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 19th, 2024. Additionally, they will participate in the Canaccord MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 21st, 2024.
KORU Medical Systems presented data at the PODD 2024 Conference showing strong nursing preference for their FreedomEdge® Infusion System over manual syringe administration for subcutaneous oncology infusions. The study, conducted across 6 Danish hospitals with 33 nurses performing over 3,000 infusions, revealed significant advantages: 97% of nurses reported more patient interaction time, 81% experienced less hand pain, 91% found it easier to use, and 73% observed reduced patient discomfort. The company plans to file for FDA clearance with an oncology biologic in 2025.
